A new study shows that the stool-based mSDC2 methylation test may significantly improve the detection of colorectal cancer (CRC) and advanced colorectal neoplasia (ACN). The prospective trial found that the mSDC2 test outperformed traditional screening methods like the fecal immunochemical test (FIT), particularly in early-stage detection. The mSDC2 test also demonstrated cost-effectiveness by reducing the need for colonoscopies. These findings suggest that mSDC2 could enhance CRC screening programs and optimize resource use in community practice.
Keep Reading
Add A Comment